{
    "organizations": [],
    "uuid": "120d0aeffc886f0204509de5623abd90a3314867",
    "author": "Peter Loftus",
    "url": "https://www.wsj.com/articles/fda-panel-backs-proposed-epilepsy-drug-derived-from-cannabis-1524156834",
    "ord_in_thread": 0,
    "title": "FDA Panel Backs Proposed Epilepsy Drug Derived From Cannabis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "An advisory panel to the Food and Drug Administration recommended the agency approve what could become the first prescription drug in the U.S. derived from the marijuana plant, as a treatment for people with rare forms of epilepsy.\n\nA committee on Thursday voted 13-0 that the risk-benefit profile was favorable for GW Pharmaceuticals PLCâ€™s drug, cannabidiol, to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. The rare disorders involve frequent or difficult-to-treat...  ",
    "published": "2018-04-19T20:53:00.000+03:00",
    "crawled": "2018-04-20T01:44:12.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "advisory",
        "panel",
        "food",
        "drug",
        "administration",
        "recommended",
        "agency",
        "approve",
        "could",
        "become",
        "first",
        "prescription",
        "drug",
        "derived",
        "marijuana",
        "plant",
        "treatment",
        "people",
        "rare",
        "form",
        "epilepsy",
        "committee",
        "thursday",
        "voted",
        "profile",
        "favorable",
        "gw",
        "pharmaceutical",
        "plc",
        "drug",
        "cannabidiol",
        "treat",
        "seizure",
        "associated",
        "syndrome",
        "dravet",
        "syndrome",
        "patient",
        "year",
        "age",
        "older",
        "rare",
        "disorder",
        "involve",
        "frequent"
    ]
}